Japanese Drugmaker Halts Skin Treatment Trials Over Cancer Concerns

Pharmaceutical company Kyowa Kirin has terminated all clinical trials for an experimental skin condition medication after safety reviews revealed potential cancer risks. The drug was being tested to treat severe eczema and other inflammatory skin disorders.

A Japanese pharmaceutical company announced Tuesday it is shutting down all clinical trials for a promising skin condition medication following safety concerns that emerged during recent reviews.

Kyowa Kirin made the decision to halt development of rocatinlimab, an experimental treatment that was undergoing testing for severe eczema, prurigo nodularis, and moderate-to-severe asthma. These conditions typically cause patients to experience dry, irritated, and inflamed skin.

Company officials determined that continuing the trials posed too great a risk to patient safety after conducting a comprehensive safety analysis of their global testing program.

The safety evaluation, completed over recent weeks, revealed troubling patterns of cancerous tumors that appeared connected to viral or immune system complications. Investigators discovered two additional cases of Kaposi’s sarcoma – a rare form of skin cancer – bringing the total to three confirmed or suspected cases among trial participants.

The experimental medication works by blocking OX40, a specific protein involved in inflammatory responses and immune system reactions throughout the body.

“This is deeply disappointing news, as we had hoped to bring a safe and effective treatment to patients,” stated Abdul Mullick, who serves as chief operating officer for Kyowa Kirin.

The pharmaceutical company had previously ended its partnership with Amgen for developing and marketing this treatment earlier in 2024.

Kyowa Kirin is now working to inform medical researchers conducting the trials and government regulatory agencies about the termination. The company plans to release additional information once they complete their comprehensive data analysis.

Moving forward, Kyowa Kirin will maintain control over all aspects of the rocatinlimab program, including any required regulatory submissions and potential future development plans.